Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from OKYO Pharma Limited Sponsored ADR ( (OKYO) ) is now available.
On April 7, 2026, OKYO Pharma announced it will convene a key Scientific Advisory Board meeting with leading ophthalmology experts during the 2026 American Society of Cataract and Refractive Surgery Annual Meeting in Washington, D.C. The board will review clinical data for urcosimod, the company’s lead candidate, and advise on the design of its upcoming clinical program, signaling a pivotal step as OKYO prepares for larger late-stage trials.
In parallel, principal investigator Dr. Pedram Hamrah will present Phase 2 proof-of-concept efficacy and safety results for urcosimod in neuropathic corneal pain in an ASCRS scientific session on April 11, 2026, underscoring growing clinical validation for the drug. Urcosimod, which has Fast Track status and has already delivered positive Phase 2 outcomes in both neuropathic corneal pain and dry eye disease, positions OKYO to address a significant unmet need in ocular pain and could enhance its standing among ophthalmic drug developers as it moves toward a planned 150-patient Phase 2b/3 study this year.
The most recent analyst rating on (OKYO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is primarily held down by weak financial fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Improved 2025 cost control and a debt-free balance sheet provide only limited offset.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market that focuses on developing innovative therapies for neuropathic corneal pain and inflammatory eye diseases. Its lead drug candidate, urcosimod, a ChemR23 agonist targeting ocular immune and neuronal pathways, has shown promising anti-inflammatory and pain-reducing effects in both preclinical models and Phase 2 clinical trials for neuropathic corneal pain and dry eye disease.
Average Trading Volume: 263,600
Technical Sentiment Signal: Sell
Current Market Cap: $80.65M
See more insights into OKYO stock on TipRanks’ Stock Analysis page.